Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rivian Automotive, Inc. (RIVN) vs Viatris Inc (VTRS) Price & Performance

Rivian Automotive, Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Rivian Automotive, Inc. vs Viatris Inc — how do they compare? Rivian Automotive, Inc. trades at $16.04 (market cap $23.41B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Viatris Inc pays a 2.89% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.

RIVNVTRS
Market Cap
$23.41B$19.09B
Sector
Consumer CyclicalHealth
52-Week High
$22.45$17.86
52-Week Low
$12.50$9.49
Enterprise Value
$23.45B$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.

RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS